Sam Smith on the Association Between Adherence and Menopausal Symptoms

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

T-DXd led to an ORR of 59.4% vs 33.9% with chemo, regardless of biomarker status, in HR+, HER2-low metastatic breast cancer, per DESTINY-Breast06.

October 2nd 2023

T-DXd Rechallenge Tolerable Post Grade 1 ILD in Breast, Solid Tumors

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

Chris Ryan

June 2nd 2025

Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

Seventy-three percent of patients with breast and other solid tumors did not experience ILD recurrence when rechallenged with trastuzumab.

January 16th 2023

Sacituzumab Govitecan/Pembrolizumab Backed as New SOC in PD-L1+ TNBC

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.

Kristi Rosa

Vepdegestrant Increases PFS in ESR1-Mutated ER+/HER2- Breast Cancer

Sacituzumab govitecan/pembrolizumab in the first line lengthened PFS vs chemotherapy/pembrolizumab in PD-L1+ metastatic triple-negative breast cancer.

Anatomical rendering of a breast with a tumor

Caroline Seymour

T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations

Patients with ESR1-mutated, ER-positive, HER2-negative, advanced breast cancer experienced an increase in PFS with vepdegestrant compared with fulvestrant.

Related Content

Tim Cortese

June 11th 2025

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

T-DXd led to an ORR of 59.4% vs 33.9% with chemo, regardless of biomarker status, in HR+, HER2-low metastatic breast cancer, per DESTINY-Breast06.

October 2nd 2023

T-DXd Rechallenge Tolerable Post Grade 1 ILD in Breast, Solid Tumors

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

Chris Ryan

June 2nd 2025

Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

Seventy-three percent of patients with breast and other solid tumors did not experience ILD recurrence when rechallenged with trastuzumab.

January 16th 2023

Sacituzumab Govitecan/Pembrolizumab Backed as New SOC in PD-L1+ TNBC

Kristi Rosa

Vepdegestrant Increases PFS in ESR1-Mutated ER+/HER2- Breast Cancer

Sacituzumab govitecan/pembrolizumab in the first line lengthened PFS vs chemotherapy/pembrolizumab in PD-L1+ metastatic triple-negative breast cancer.

Caroline Seymour